Delivery Order SPE2DB20D9214-SPE2DB25FD4SZ

Award Date 2/26/25
Potential Completion Date 3/19/25
Potential Value $15K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,474.00 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product, with a period of performance through January 2, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This federal contract award, valued at $7,737.00, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Xolair 150 mg/ml syringes, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $9,284.40 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which covers a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $37,137.60 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product. This order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which covers a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,547.40 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product, with an ultimate completion date of October 10, 2024. The contract is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,094.80 firm fixed-price delivery order is for the provision of XOLAIR 150 MG/ML SYRINGE medication with a completion date of December 12, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $9,284.40, is a firm fixed-price delivery order for the supply of XOLAIR 150 MG/ML SYRINGEML, a pharmaceutical product. The award is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which runs through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $10,831.80, is a firm fixed-price delivery order for the supply of XOLAIR 150 MG/ML SYRINGE, a specialized pharmaceutical product. The award is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which...
This federal contract award is for a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $58,027.50, was awarded by the Defense Logistics Agency (DLA) for the supply of Xolair 150mg/ml syringes. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a...
This federal contract award, valued at $15,474.00, was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of XOLAIR 150 MG/ML SYRINGEML, with a completion date of September 19, 2024. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up...
  • SPE2DB20D9214
    Indefinite Delivery Contract
  • SPE2DB20D9214-SPE2DB25FD4SZ
    Delivery Order

The federal contract award, valued at $15,474.00, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract does not have a set-aside designation, allowing DMS Pharmaceutical Group Inc. to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.

Generated 5/28/25, 11:04 AM